The Role of Hypofractionated Radiotherapy in Prostate Cancer
Open Access
- 25 March 2017
- journal article
- review article
- Published by Springer Nature in Current Oncology Reports
- Vol. 19 (4) , 1-9
Abstract
Purpose of Review It is now accepted that prostate cancer has a low alpha/beta ratio, establishing a strong basis for hypofractionation of prostate radiotherapy. This review focuses on the rationale for hypofractionation and presents the evidence base for establishing moderate hypofractionation for localised disease as the new standard of care. The emerging evidence for extreme hypofractionation in managing localized and oligometastatic prostate cancer is reviewed. Recent Findings The 5-year efficacy and toxicity outcomes from four phase III studies have been published within the last 12 months. These studies randomizing over 6000 patients to conventional fractionation (1.8–2.0 Gy per fraction) or moderate hypofractionation (3.0–3.4 Gy per fraction). They demonstrate hypofractionation to be non-inferior to conventional fractionation. Summary Moderate hypofractionation for localized prostate cancer is safe and effective. There is a growing body of evidence in support of extreme hypofractionation for localized prostate cancer. Extreme hypofractionation may have a role in managing prostate oligometastases, but further studies are needed.Keywords
This publication has 63 references indexed in Scilit:
- Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early resultsRadiation Oncology, 2013
- Stereotactic Body Radiation Therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experienceRadiation Oncology, 2013
- Inhibition of COX-2 expression by topical diclofenac enhanced radiation sensitivity via enhancement of TRAIL in human prostate adenocarcinoma xenograft modelBMC Urology, 2013
- Integration method of 3D MR spectroscopy into treatment planning system for glioblastoma IMRT dose painting with integrated simultaneous boostRadiation Oncology, 2013
- Meta-analysis of the Alpha/Beta Ratio for Prostate Cancer in the Presence of an Overall Time Factor: Bad News, Good News, or No News?International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2013
- Robotic Image-Guided Stereotactic Radiotherapy, for Isolated Recurrent Primary, Lymph Node or Metastatic Prostate CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012
- Randomized Trial Comparing Conventional-Dose With High-Dose Conformal Radiation Therapy in Early-Stage Adenocarcinoma of the Prostate: Long-Term Results From Proton Radiation Oncology Group/American College of Radiology 95-09Journal of Clinical Oncology, 2010
- Screening and Prostate-Cancer Mortality in a Randomized European StudyNew England Journal of Medicine, 2009
- The Linear-Quadratic Model Is an Appropriate Methodology for Determining Isoeffective Doses at Large Doses Per FractionSeminars in Radiation Oncology, 2008
- The linear-quadratic formula and progress in fractionated radiotherapyBritish Journal of Radiology, 1989